EGFR and non-small cell lung carcinoma: Another clinical trial (ADJUVANT) reported that for NSCLC with stage II–IIIA EGFR alterations, adjuvant gefitinib (28.7 months) resulted in significantly longer median DFS than vinorelbine plus cisplatin (18 months) [59].